JPH08500827A - 異化症状および全身性組織創傷の全身的治療方法 - Google Patents
異化症状および全身性組織創傷の全身的治療方法Info
- Publication number
- JPH08500827A JPH08500827A JP6506611A JP50661194A JPH08500827A JP H08500827 A JPH08500827 A JP H08500827A JP 6506611 A JP6506611 A JP 6506611A JP 50661194 A JP50661194 A JP 50661194A JP H08500827 A JPH08500827 A JP H08500827A
- Authority
- JP
- Japan
- Prior art keywords
- igf
- igfbp
- complex
- individual
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 72
- 208000027418 Wounds and injury Diseases 0.000 title claims description 24
- 206010052428 Wound Diseases 0.000 title claims description 22
- 238000011282 treatment Methods 0.000 title claims description 21
- 230000009885 systemic effect Effects 0.000 title description 8
- 230000015556 catabolic process Effects 0.000 title description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims abstract description 131
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 claims abstract description 108
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 claims abstract description 108
- 102000013275 Somatomedins Human genes 0.000 claims abstract description 80
- 239000000203 mixture Substances 0.000 claims abstract description 31
- 238000001356 surgical procedure Methods 0.000 claims abstract description 27
- 230000001925 catabolic effect Effects 0.000 claims abstract description 13
- 208000008469 Peptic Ulcer Diseases 0.000 claims abstract description 12
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims abstract description 10
- 230000008733 trauma Effects 0.000 claims abstract description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 52
- 102000028416 insulin-like growth factor binding Human genes 0.000 claims description 50
- 108091022911 insulin-like growth factor binding Proteins 0.000 claims description 50
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims description 26
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims description 26
- 229910052757 nitrogen Inorganic materials 0.000 claims description 26
- 230000035876 healing Effects 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 230000037396 body weight Effects 0.000 claims description 12
- 238000010254 subcutaneous injection Methods 0.000 claims description 11
- 239000007929 subcutaneous injection Substances 0.000 claims description 11
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 10
- 238000007910 systemic administration Methods 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- 239000003862 glucocorticoid Substances 0.000 claims description 9
- 230000017423 tissue regeneration Effects 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 208000014674 injury Diseases 0.000 claims description 8
- 241000271566 Aves Species 0.000 claims description 7
- 208000025865 Ulcer Diseases 0.000 claims description 7
- 231100000397 ulcer Toxicity 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 208000011906 peptic ulcer disease Diseases 0.000 claims description 6
- 241000287828 Gallus gallus Species 0.000 claims description 5
- 101001044927 Homo sapiens Insulin-like growth factor-binding protein 3 Proteins 0.000 claims description 5
- 230000002496 gastric effect Effects 0.000 claims description 5
- 102000057148 human IGFBP3 Human genes 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 102000044162 human IGF1 Human genes 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 4
- 241000272517 Anseriformes Species 0.000 claims description 3
- 241000282472 Canis lupus familiaris Species 0.000 claims description 3
- 208000010399 Wasting Syndrome Diseases 0.000 claims description 3
- 239000007928 intraperitoneal injection Substances 0.000 claims description 3
- 238000010253 intravenous injection Methods 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 2
- 241000283086 Equidae Species 0.000 claims description 2
- 241000282326 Felis catus Species 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 241000272525 Anas platyrhynchos Species 0.000 claims 1
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 claims 1
- 102000057877 human IGF2 Human genes 0.000 claims 1
- 206010044546 Traumatic ulcer Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 30
- 230000000694 effects Effects 0.000 description 26
- 230000001965 increasing effect Effects 0.000 description 18
- 210000003205 muscle Anatomy 0.000 description 17
- 239000003925 fat Substances 0.000 description 16
- 241000700159 Rattus Species 0.000 description 15
- 230000029663 wound healing Effects 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 108010051696 Growth Hormone Proteins 0.000 description 8
- 102100038803 Somatotropin Human genes 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000000122 growth hormone Substances 0.000 description 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 239000003102 growth factor Substances 0.000 description 7
- 238000009806 oophorectomy Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 6
- 102000004375 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 6
- 108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 description 6
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 150000003431 steroids Chemical class 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 235000021476 total parenteral nutrition Nutrition 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 235000019786 weight gain Nutrition 0.000 description 6
- 102000014914 Carrier Proteins Human genes 0.000 description 5
- 102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 description 5
- 108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 description 5
- 210000000579 abdominal fat Anatomy 0.000 description 5
- 108091008324 binding proteins Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000002218 hypoglycaemic effect Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 4
- 208000013016 Hypoglycemia Diseases 0.000 description 4
- 102000004369 Insulin-like growth factor-binding protein 4 Human genes 0.000 description 4
- 108090000969 Insulin-like growth factor-binding protein 4 Proteins 0.000 description 4
- 102000004883 Insulin-like growth factor-binding protein 6 Human genes 0.000 description 4
- 108090001014 Insulin-like growth factor-binding protein 6 Proteins 0.000 description 4
- 102000007562 Serum Albumin Human genes 0.000 description 4
- 108010071390 Serum Albumin Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 4
- 229960000890 hydrocortisone Drugs 0.000 description 4
- 229960002591 hydroxyproline Drugs 0.000 description 4
- 230000002608 insulinlike Effects 0.000 description 4
- 229940037128 systemic glucocorticoids Drugs 0.000 description 4
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 206010006895 Cachexia Diseases 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 108090000961 Insulin-like growth factor binding protein 5 Proteins 0.000 description 3
- 102000004371 Insulin-like growth factor binding protein 5 Human genes 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000013330 chicken meat Nutrition 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 102000007584 Prealbumin Human genes 0.000 description 2
- 108010071690 Prealbumin Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000008468 bone growth Effects 0.000 description 2
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 238000004581 coalescence Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004199 lung function Effects 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 229960002378 oftasceine Drugs 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 101710201712 Amino acid binding protein Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000034920 Body Weight Maintenance Diseases 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007191 Capillary fragility Diseases 0.000 description 1
- 206010007733 Catabolic state Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010056438 Growth hormone deficiency Diseases 0.000 description 1
- 101001081567 Homo sapiens Insulin-like growth factor-binding protein 1 Proteins 0.000 description 1
- 101001044940 Homo sapiens Insulin-like growth factor-binding protein 2 Proteins 0.000 description 1
- 101000840566 Homo sapiens Insulin-like growth factor-binding protein 5 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 102000021052 amino acid binding proteins Human genes 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 235000021051 daily weight gain Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 229960002398 demeclocycline Drugs 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 102000047065 human IGFBP1 Human genes 0.000 description 1
- 102000050770 human IGFBP2 Human genes 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- -1 plasma preparations Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.異化症状について個体を処置する方法であって、該方法が、該個体 にインスリン様成長因子(IGF)およびインスリン様成長因子結合タンパク質−3( IGFBP-3)を含有する複合体を非経口投与する工程を包含し、該複合体が該症状を 緩和するに十分な量で投与される、方法。 2.前記複合体が等モル量のIGFおよびIGFBP-3を含有する、請求項1に 記載の方法。 3.前記IGFがIGF-Iである、請求項1に記載の方法。 4.前記IGFが組換えヒトIGF-Iである、請求項1に記載の方法。 5.前記IGFがIGF-IIである、請求項1に記載の方法。 6.前記IGF-IIが組換えヒトIGF-IIである、請求項5に記載の方法。 7.前記IGFBP-3が組換えヒトIGFBP-3である、請求項1および5に記載 の方法。 8.前記異化症状がタンパク質消耗性疾患である、請求項1に記載の方 法。 9.前記投与が皮下注射により行われる、請求項1に記載の方法。 10.治療上の有効量が、前記個体においてポジティブ窒素バランスを 生じる複合体の量である、請求項1に記載の方法。 11.前記複合体投与量が、少なくとも約0.05mg IGF/kg体重/日である 、請求項1に記載の方法。 12.前記個体が哺乳類または鳥類の個体である、請求項1に記載の方 法。 13.前記個体が、ウシ、ブタ、ヒツジ、ニワトリ、七面鳥、アヒル、 ガチョウ、イヌ、ウマ、ネコ、およびぺット用の鳥からなる群より選択される、 請求項12に記載の方法。 14.手術を行う予定である、行っている、または行ったところである 個体における軟組織および硬組織の修復を増強する方法であって、該方法が、該 個体にIGFおよびIGF BPを含有する治療用組成物を全身投与する工程を包含し、該IGFおよびIGFBPが、 該個体における軟組織および硬組織の修復を増強するに十分な量で投与される、 方法。 15.火傷を受けた個体を処置する方法であって、該方法が、IGFおよ びIGFBPを含有する治療用組成物を該個体の該火傷の治癒を増強するに十分な量 で該個体に全身投与する工程を包含する、方法。 16.外傷による損傷を受けた個体を処置する方法であって、該方法が 、IGFおよびIGFBPを含有する治療用組成物を該外傷の治癒を増強するに十分な量 で該個体に全身投与する工程を包含する、方法。 17.消化性潰瘍を有する個体を処置する方法であって、該方法が、IG FおよびIGFBPを含有する治療用組成物を該潰瘍の治癒を増強するに十分な量で該 個体に全身投与する工程を包含する、方法。 18.手術を受けている前記個体が、腫瘍を切除されている、臓器摘出 または移植をされている、グルココルチコイド処置を受けている、または糖尿病 である、請求項14〜17に記載の方法。 19.前記複合体の全身投与が、非経口投与、胃腸管内投与、および鼻 腔内投与を包含する、請求項14〜17に記載の方法。 20.前記非経口投与が、皮下注射、静脈内注射、腹腔内注射、および 筋肉内注射を包含する、請求項14〜17および19に記載の方法。 21.前記IGFがIGF-Iである、請求項14〜17に記載の方法。 22.前記IGF-Iが組換えヒトIGF-Iである、請求項14〜17および2 1に記載の方法。 23.前記IGFBPがIGFBP-3である、請求項14〜17に記載の方法。 24.前記IGFBP-3が組換えヒトIGFBP-3である、請求項14〜17およ び23に記載の方法。 25.組換えヒトIGFBP-3がグリコシル化されていない、請求項14〜 17および24に記載の方法。 26.前記IGFの投与量が少なくとも約0.1〜5mg I GF/kg体重/日である、請求項14〜17に記載の方法。 27.IGFがほぽ等モル量のIGFBPに複合休化する、請求項14〜17お よび26に記載の方法。 28.前記個体が哺乳類または鳥類である、請求項14〜17に記載の 方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93589092A | 1992-08-26 | 1992-08-26 | |
US07/935,890 | 1992-08-26 | ||
US07/984,936 US5407913A (en) | 1992-12-03 | 1992-12-03 | Method and composition for systemic treatment of tissue injury |
US07/984,936 | 1992-12-03 | ||
PCT/US1993/008025 WO1994004030A1 (en) | 1992-08-26 | 1993-08-26 | Method for systemic treatment of catabolic conditions and systemic tissue injury |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH08500827A true JPH08500827A (ja) | 1996-01-30 |
Family
ID=27130081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6506611A Pending JPH08500827A (ja) | 1992-08-26 | 1993-08-26 | 異化症状および全身性組織創傷の全身的治療方法 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0661990B1 (ja) |
JP (1) | JPH08500827A (ja) |
AT (1) | ATE215835T1 (ja) |
CA (1) | CA2142455A1 (ja) |
DE (1) | DE69331802T2 (ja) |
DK (1) | DK0661990T3 (ja) |
ES (1) | ES2174852T3 (ja) |
PT (1) | PT661990E (ja) |
WO (1) | WO1994004030A1 (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR960700069A (ko) * | 1993-01-29 | 1996-01-19 | 다니엘 바프네크 | 상처 치료용 조성물(wound healing composition) |
WO1995014093A1 (en) * | 1993-05-19 | 1995-05-26 | Institut Pasteur | Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions and nucleic acid sequences encoding said polypeptides |
AUPM678294A0 (en) * | 1994-07-13 | 1994-08-04 | Gropep Pty Ltd | Use of insulin-like growth factor in combination with insulin |
WO1996002565A1 (en) * | 1994-07-20 | 1996-02-01 | Celtrix Pharmaceuticals, Inc. | Igf/igfbp complex for promoting bone formation and for regulating bone remodeling |
US5741776A (en) * | 1995-05-22 | 1998-04-21 | Genentech, Inc. | Method of administration of IGF-I |
CA2232000A1 (en) * | 1995-09-14 | 1997-03-20 | Bristol-Myers Squibb Company | Insulin-like growth factor binding protein 3 (igf-bp3) in treatment of p53-related tumors |
ES2293137T3 (es) * | 1995-10-11 | 2008-03-16 | Novartis Vaccines And Diagnostics, Inc. | Combinacion de pdgf, kgf,igf e igfbp para curacion de heridas. |
US5783556A (en) * | 1996-08-13 | 1998-07-21 | Genentech, Inc. | Formulated insulin-containing composition |
US6156728A (en) | 1996-11-01 | 2000-12-05 | Genentech, Inc. | Treatment of inner ear hair cells |
US6593290B1 (en) * | 1996-11-01 | 2003-07-15 | Genentech, Inc. | Treatment of inner ear hair cells |
US6514937B1 (en) * | 1997-02-25 | 2003-02-04 | Celtrix Pharmaceuticals, Inc. | Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3 |
US5998369A (en) * | 1997-05-05 | 1999-12-07 | Mayo Foundation For Medical Education And Research | Treatment of osteoporosis |
US6916790B2 (en) | 1997-05-05 | 2005-07-12 | Mayo Foundation For Medical Education And Research | Treatment of osteoporosis |
GB2369572A (en) | 2000-11-29 | 2002-06-05 | Raft Trustees Ltd | Wound treatment composition comprising insulin |
WO2020006273A1 (en) * | 2018-06-27 | 2020-01-02 | Juvena Therapeutics, Inc. | Heparin-associated polypeptides and uses thereof |
CN108998463A (zh) * | 2018-08-24 | 2018-12-14 | 苏州红冠庄国药股份有限公司 | 一种人源胰岛素生长因子-1(igf-1)复合物的制备工艺 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5187151A (en) * | 1991-02-12 | 1993-02-16 | Genentech, Inc. | Use of binding protein with igf-i as an anabolic growth promoting agent |
-
1993
- 1993-08-26 WO PCT/US1993/008025 patent/WO1994004030A1/en active IP Right Grant
- 1993-08-26 ES ES93920354T patent/ES2174852T3/es not_active Expired - Lifetime
- 1993-08-26 DK DK93920354T patent/DK0661990T3/da active
- 1993-08-26 EP EP93920354A patent/EP0661990B1/en not_active Expired - Lifetime
- 1993-08-26 AT AT93920354T patent/ATE215835T1/de not_active IP Right Cessation
- 1993-08-26 JP JP6506611A patent/JPH08500827A/ja active Pending
- 1993-08-26 DE DE69331802T patent/DE69331802T2/de not_active Expired - Fee Related
- 1993-08-26 CA CA002142455A patent/CA2142455A1/en not_active Abandoned
- 1993-08-26 PT PT93920354T patent/PT661990E/pt unknown
Also Published As
Publication number | Publication date |
---|---|
EP0661990B1 (en) | 2002-04-10 |
DE69331802T2 (de) | 2002-11-07 |
EP0661990A1 (en) | 1995-07-12 |
WO1994004030A1 (en) | 1994-03-03 |
EP0661990A4 (en) | 1995-05-22 |
DE69331802D1 (de) | 2002-05-16 |
PT661990E (pt) | 2002-09-30 |
ES2174852T3 (es) | 2002-11-16 |
DK0661990T3 (da) | 2002-06-17 |
CA2142455A1 (en) | 1994-03-03 |
ATE215835T1 (de) | 2002-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5187151A (en) | Use of binding protein with igf-i as an anabolic growth promoting agent | |
US5407913A (en) | Method and composition for systemic treatment of tissue injury | |
US5374620A (en) | Growth-promoting composition and its use | |
US5681814A (en) | Formulated IGF-I Composition | |
EP0536226B1 (en) | The combination of growth hormone and insulin-like growth factor-i enhances growth | |
JP2831017B2 (ja) | 高インシュリン症の二次効果治療及び予防用医薬組成物 | |
Hirschberg et al. | Insulin-like growth factor system and the kidney: physiology, pathophysiology, and therapeutic implications | |
JPH08500827A (ja) | 異化症状および全身性組織創傷の全身的治療方法 | |
US5939387A (en) | Method of treating insulin resistance | |
WO1994004030A9 (en) | Method for systemic treatment of catabolic conditions and systemic tissue injury | |
KR20080110852A (ko) | 대사질환 치료용 엔도테린 및 엔도테린 수용체 작용제 | |
EP0732933A1 (en) | Method of treating renal disease by administering igf-i and igfbp-3 | |
NZ252359A (en) | Use of igf-1 | |
EZZAT et al. | Octreotide stimulates insulin-like growth factor binding protein-1 (IGFBP-1) levels in acromegaly | |
JPH09507832A (ja) | Igfbp単独またはigfbpとigfとの複合体による免疫疾患および血液疾患の処置 | |
Koea et al. | Anabolic and cardiovascular effects of recombinant human growth hormone in surgical patients with sepsis | |
US5643867A (en) | Method for treating catabolic conditions | |
AU755897B2 (en) | Methods of Increasing Sex Hormone Binding Globulin (SHBG) in a Subject | |
JPH10502368A (ja) | インシュリン及びigf−iの使用 | |
US5948757A (en) | High dose IGF-1 therapy | |
Quin | The insulin-like growth factors | |
Hatton et al. | Growth factors in nutritional support | |
AU2022276512A1 (en) | Methods and compositions for inducing brown adipogenesis | |
JPH07316071A (ja) | 筋ジストロフィー治療薬 | |
JPH0827024A (ja) | 口腔粘膜疾患治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20031208 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20031208 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20031222 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040223 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040322 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040322 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050329 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050627 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050812 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20050901 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20051215 |